• Panagiota Economopoulou, Ioannis Kotsantis, and Aristotelis Bamias.
• Second Department of Internal Medicine, Propaedeutic, National & Kapodistrian University of Athens, Attikon University Hospital , Athens, Greece.
• Expert Opin Drug Saf. 2020 Aug 1; 19 (8): 955-960.

IntroductionImmune checkpoint inhibitors (ICIs) have rapidly changed the treatment landscape, demonstrating dramatic clinical efficacy in various cancers.Areas CoveredIn urothelial cancer (UC), several ICIs have been approved in platinum refractory disease and also as first-line therapy in patients that fulfill the criteria for cisplatin ineligibility. Atezolizumab is a monoclonal antibody that targets the immune checkpoint Programmed Cell Death Ligand-1 (PD-L1) and has been currently approved for advanced UC, non-small cell lung cancer, small cell lung cancer, and triple-negative breast cancer. Herein, we provide a summary of the mechanism of action, safety, and clinical efficacy of atezolizumab in UC.Expert OpinionAtezolizumab is a drug with a favorable toxicity profile and will obtain more indications in the future in UC and other cancers. Treating physicians should be aware of treatment-related and immune-related adverse events associated with the drug.

22 keywords...

hide…